Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Go back to Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 104.71 +1.05 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $103.66 | 52 Week High | $118.49 | |||
| Open | $104.61 | 52 Week Low | $55.00 | |||
| Day High | $105.48 | P/E | N/A | |||
| Day Low | $103.07 | EPS | $-0.56 | |||
| Volume | 725,862 | |||||
| (NASDAQ: MIRM) | Delayed: 109.73 +1.96 (1.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.77 | 52 Week High | $ | |||
| Open | $105.48 | 52 Week Low | $ | |||
| Day High | $110.18 | P/E | N/A | |||
| Day Low | $105.18 | EPS | $ | |||
| Volume | 693,368 | |||||
